Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on RAVEN RUSSIA LTD. We currently have 22 research reports from 4 professional analysts.
|03Jan17 07:05||RNS||Director/PDMR Shareholding|
|03Jan17 07:00||RNS||Total Voting Rights|
|30Dec16 07:00||RNS||Issue of Preference Shares|
|21Dec16 04:00||RNS||Director/PDMR Shareholding|
|08Dec16 04:00||RNS||Director/PDMR Shareholding|
|01Dec16 07:00||RNS||Convertible Preference Share Dividend|
|24Nov16 07:00||RNS||Scrip Dividend Circular|
Frequency of research reports
Research reports on
RAVEN RUSSIA LTD
RAVEN RUSSIA LTD
N+1 Singer - Small-cap quantitative research - Re-run of the value screen and 9 focus stocks
10 Nov 16
We have completed another periodic refresh of our value style screen, first established in our note of 26 May 2015. As usual the screen selected the 25 stocks exhibiting the most extreme value characteristics from our universe, and we have chosen 9 stocks to focus on. Since inception last year the screen has marginally outperformed the main small-cap index by 1pp and underperformed the micro-cap index by about 3pp. The EU referendum result arose in the latest period and resulted in significant short-term underperformance, which has not been recovered. The new basket was struck before the US election result.
Robust performance and financial strength
31 Aug 16
Market conditions, echoing economic developments, show signs of stabilising and occupancy levels have held at 82% over the period, in line with our forecast. The company’s active leasing efforts, aimed at defending income and cash flow, have dealt with the majority of the 2016 lease maturities. Costs are being contained and the cash balance has remained strong even before July’s £109m issue of convertible preference shares. Raven is well placed to navigate current market conditions and seize opportunities in an upturn.
Cash is King
30 Aug 16
Raven Russia has held its own in turbulent times, and has gone one better than this. Net operating income (‘NOI’) showed only a small decline versus H2 2015, and the balance sheet has been enormously strengthened by the issue of convertible preference shares in July. This is clearly a statement of intent that the company is here to stay and will remain a major force in the future of the Russian property market.
N+1 Singer - Morning Song 30-08-2016
30 Aug 16
Verona Pharma will present three abstracts at the European Respiratory Society (ERS) 2016 International Conference with one ‘Late-Breaking abstract’ presentation providing detailed results from its Phase IIa ‘add-on’ trial with RPL554. Verona Pharma continues to announce positive results with its proprietary suspension formulation of its first-in-class dual inhibitor. RPL554 has demonstrated an attractive profile with its combined bronchodilator and anti-inflammatory properties, representing a novel approach to the treatment of respiratory disease. The recent £44.7m equity capital raise enables the group to progress its development of RPL554 through to a Phase III ready stage. If development goes according to plan, RPL554 could be in a position to commence Phase III trials by the end of 2018. We remain upbeat on Verona and look forward to the commencement of Phase IIb trials in H1 2017.
N+1 Singer - Raven Russia Ltd - Signs of stability
30 Aug 16
Raven Russia has delivered essentially in line half-year results, managing the continued decline in rental income, while at the same time preserving cash and maintaining NAV per share. Activity levels in the Russian warehouse market have improved amid a general stabilisation of the domestic economy. While geopolitical risks remain in the background, the apparent stability returning to the market and the company’s balance sheet restructuring measures boosting both liquidity and cash-flow suggest the 32% discount to NAV has, in our view, plenty of scope to narrow.
N+1 Singer - Small-cap quantitative research - New momentum screen + 10 “trendy friendlies”
28 Jul 16
We present here our new momentum screen, which is intended to track the behaviour of small-cap shares experiencing the most positive technical momentum. This represents the third of our style baskets, with value and consistent growth themes already established. This is not intended to address the perennial tension between technical and fundamental analysts, merely to investigate behaviour over time. Of the 25 stocks in the basket, we have focussed on 10 which we know and believe to be particularly interesting. With the widely used dictum “the trend is your friend” in mind, we have dubbed them the “trendy friendlies”. We will monitor performance and refresh the screen in 3-4 months’ time.
Making Mobiles Better
17 Jan 17
Mobile phones are increasingly the key connection for the modern world. This means that the performance of mobile phones, and their networks, is going to become more critical for all the apps and businesses that rely on them. New technologies such as VR, AR, and AV will need better, more reliable connections to really move into the mainstream. In this thematic piece we attempt to identify some of the most important issues facing mobile phone networks and their users, and start to identify solutions and enablers that will solve these problems and create value by doing so.
N+1 Singer - Best Ideas 2017 - Top picks
04 Jan 17
Today we publish our Best Ideas for 2017 - 12 stocks that we believe have excellent prospects in the current year together with a detailed discussion of what we see as the key sector and market themes for 2017. Our top picks are Cineworld, Elementis, Herald Investment Trust, Hill & Smith, IQE, MySale, Redde, ReNeuron, RhythmOne, SDL, Servelec and Severfield.
The Monthly January 2017
09 Jan 17
Despite all the hullaballoo of the Brexit vote and the subsequent election of Donald Trump as the next US President, the UK stock market prospered last year, especially in the latter few months of 2016. The combination of a depreciating currency – making $ earnings more valuable in relative terms - and the Trump emphasis on infrastructure expenditure drove the stock market higher
Small Cap Breakfast
17 Jan 17
Global Energy Development (GED.L) — To be renamed Nautilus Marine Services. Schedule 1 from developer and seller of hydrocarbons and related products. Reverse takeover. Raising $10.5m via a convertible. Expected 9 Feb. Eco (Atlantic) Oil & Gas—TSX-V listed oil and gas exploration has announced its intention to float on AIM. Assets in Guyana and Namibia. Proposed £2m-£3m fundraise. Diversified Gas & Oil—According to LSE website first day of trading on AIM now expected for 30 January.
N+1 Singer - Morning Song 16-01-2017
16 Jan 17
As the birthplace of Stephenson, Armstrong and Swan, the North East of England has a proud history of industrial and technological innovation. Despite local economic challenges, the region’s industrial heritage lives on through continuing success in high end engineering and technology. The recent takeovers of private equity backed SMD (subsea robotics) and Nomad Digital (wi-fi on the railways) are testament to this. The North East has also emerged as a leader in genetics and genomics with an enviable life sciences and healthcare infrastructure. Against this backdrop, we expect the region to continue to throw up attractive IPO candidates to build on the six new listings in the past three years. We expect 2017 to be far kinder to the existing portfolio of North East plcs than 2016 (a year to forget) with recent management changes one important theme for the new year. Our top picks are Hargreaves Services, Quantum Pharma and Zytronic (all N+1 Singer Corporate clients) and we are Buyers of Northgate and Grainger.